Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Molecular Immunology|November 25, 2015
Chaperone BAG6 is dispensable for MHC class I antigen processing and presentationAnnegret Bitzer, Michael Basler, Marcus GroettrupFEBS Letters|December 8, 2016
Newly translated proteins are substrates for ubiquitin, ISG15, and FAT10Valentina Spinnenhirn, Annegret Bitzer, Annette Aichem, et al.Molecular Immunology|February 4, 2017
Immunoproteasome subunit deficiency has no influence on the canonical pathway of NF-κB activationAnnegret Bitzer, Michael Basler, Daniel Krappmann, et al.Journal of Virology|July 5, 2012
Stable antigen is most effective for eliciting CD8+ T-cell responses after DNA vaccination and infection with recombinant vaccinia virus in vivoChristopher Schliehe, Annegret Bitzer, Maries van den Broek, et al.Clinical and Experimental Rheumatology|October 13, 2015
The immunoproteasome: a novel drug target for autoimmune diseasesMichael Basler, Sarah Mundt, Annegret Bitzer, et al.Emerging Microbes & Infections|February 25, 2025
Cross-neutralizing activity of the chikungunya vaccine VLA1553 against three prevalent chikungunya lineagesKarin Kosulin, Trevor L Brasel, Jeanon Smith, et al.JCI Insight|June 14, 2022
Effectiveness of CHIKV vaccine VLA1553 demonstrated by passive transfer of human seraPierre Roques, Andrea Fritzer, Nathalie Dereuddre-Bosquet, et al.Journal of Travel Medicine|December 13, 2023
A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults†Robert McMahon, Ulrike Fuchs, Martina Schneider, et al.Lancet (London, England)|June 15, 2023
Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trialMartina Schneider, Marivic Narciso-Abraham, Sandra Hadl, et al.Nature Medicine|February 6, 2026
Live-attenuated chikungunya vaccine in children: a randomized phase 2 trialPetronela Weisová, Susanne Scheiblauer, Jacqueline Ecker, et al.Pageof 2